Taro Pharmaceutical Industries Ltd (0000906338) recently submitted a Form 15F-12B filing with the Securities and Exchange Commission (SEC). This filing is significant as it indicates that the company is deregistering a class of securities under Section 12(b) of the Securities Exchange Act of 1934. Deregistration can occur for various reasons, such as a company delisting its securities from a particular stock exchange or ceasing to have a certain number of shareholders of record.
Taro Pharmaceutical Industries Ltd is a multinational pharmaceutical company that specializes in developing, manufacturing, and marketing generic and branded prescription and over-the-counter medications. With a focus on dermatology, cardiology, and other therapeutic areas, Taro is known for its high-quality products and global presence. For more information about Taro Pharmaceutical Industries Ltd, you can visit their website at https://www.taro.com/.
Form 15F-12B is a filing with the SEC that is used by companies to deregister a class of securities under Section 12(b) of the Securities Exchange Act of 1934. This form is typically submitted when a company no longer wishes to have its securities listed on a particular stock exchange or if it no longer meets the requirements for listing. Deregistration of securities can have various implications for investors and the company itself, so it is important for stakeholders to stay informed about such filings.
Read More:
Taro Pharmaceutical Industries Ltd Submits Form 15F-12B to SEC
Leave a Reply